In terms of treatment, the advent of immune checkpoint inhibitors, such as anti-PD-1 (nivolumab and pembrolizumab) and anti-CTLA-4 (ipilimumab) antibodies, has revolutionized the management of advanced melanoma. This evidence concerns the gene CTLA4 and melanoma.